science

Relatlimab

Relatlimab is a science topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Relatlimab rather than just read about it. In short: Relatlimab is a monoclonal antibody designed for the treatment of melanoma. It is used in combination with nivolumab to treat melanoma.

Key takeaways

Relatlimab belongs to science; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Relatlimab to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Relatlimab from memory before moving on to harder problems.

Reference excerpt

Relatlimab is a monoclonal antibody designed for the treatment of melanoma. It is used in combination with nivolumab to treat melanoma. Relatlimab is a Lymphocyte activation gene-3 (LAG-3) inhibitor. It is under development by Bristol-Myers Squibb. It is made using Chinese hamster ovary cells.

History In 2004, Drew Pardoll and colleagues discovered that the lymphocyte-activation gene 3, or LAG-3, was a new immune checkpoint. Checkpoints inhibitors are proteins that stop the immune system from responding to cancer cells. Checkpoint inhibitor drugs block these proteins, unleashing the immune system to battle the cancer. As stated in the official Johns Hopkins Technological Ventures Press:

2004: Drew Pardoll discovers that LAG-3 is a new immune checkpoint. 2010: Pardoll and his research team begin a study to see how relatlimab, a LAG-3 blocking drug, treats cancer in mice. 2012: Findings from the study are published showing that a combination of a LAG-3 blocker and PD-1 blocker is an effective cancer treatment. 2016: The Join effort including Drew Pardoll, Shirley Liu, Cliff Meyer and Eduardo Gusmao has led to significant advances on the effectiveness as LAG-3 + PD-1 checkpoint blockade immunotherapy. 2018: The RELATIVITY-047 trial begins enrolling patients and randomly assigning them to receive relatlimab with nivolumab or nivolumab alone. January 2022: Results from the RELATIVITY-047 trial published in The New England Journal of Medicine show the combination treatment with relatlimab to be a more effective treatment than nivolumab alone. March 2022: The FDA gives approval for the combination treatment (relatlimab and nivolumab, marketed as Opdualag) as a new therapy for patients with metastatic or inoperable melanoma. The combination nivolumab/relatlimab (Opdualag) was approved for medical use in the United States in March 2022.

Names Relatlimab is the United States Adopted Name (USAN) and the international nonproprietary name (INN).

References

Worked examples

Example 1 — a first encounter with Relatlimab

Start with the simplest possible case. Write down what Relatlimab claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Relatlimab before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Relatlimab ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Relatlimab

In research: Relatlimab appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Relatlimab in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Relatlimab is common in secondary-school and first-year university syllabi. It links to neighbouring topics Drugs developed by Bristol Myers Squibb, Drugs not assigned an ATC code, Experimental monoclonal antibodies, so understanding it makes those chapters shorter.
In everyday life: Look for Relatlimab outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Relatlimab in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Relatlimab means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Relatlimab out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Relatlimab in simple terms?

Relatlimab is a monoclonal antibody designed for the treatment of melanoma. It is used in combination with nivolumab to treat melanoma.

Why does Relatlimab matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Relatlimab?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Relatlimab.